Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

FK506, a first-line immunosuppressant, is routinely administered orally and intravenously to inhibit activation and proliferation of T cells after heart transplantation (HT). Current administration route is not conducive enough to exert its efficacy in lymphatic system. Herein, we proposed that subc...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Cheng, Jin, Qiaofeng, Wu, Ya, Li, Huiling, Yi, Luyang, Chen, Yihan, Gao, Tang, Wang, Wenyuan, Wang, Jing, Lv, Qing, Yang, Yali, Xu, Jia, Fu, Wenpei, Zhang, Li, Xie, Mingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409942/
https://www.ncbi.nlm.nih.gov/pubmed/34463172
http://dx.doi.org/10.1080/10717544.2021.1968978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409942/
https://www.ncbi.nlm.nih.gov/pubmed/34463172
http://dx.doi.org/10.1080/10717544.2021.1968978

Ejemplares similares